|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q60718455
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241121000303.0 |
|
008
|
|
|
241121nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q60718455
|
|
024
|
|
|
‡a
0000-0003-4146-025X
‡2
orcid
|
|
035
|
|
|
‡a
(OCoLC)Q60718455
|
|
100
|
0 |
|
‡a
J. New
‡9
ast
|
|
375
|
|
|
‡a
1
‡2
iso5218
|
|
400
|
0 |
|
‡a
John New
‡c
researcher
‡9
en
|
|
400
|
0 |
|
‡a
John New
‡c
investigador
‡9
es
|
|
400
|
0 |
|
‡a
John New
‡c
forsker
‡9
nb
|
|
400
|
0 |
|
‡a
J. New
‡c
onderzoeker
‡9
nl
|
|
670
|
|
|
‡a
Author's 40 EASD Annual Meeting of de European Association give de Study of Diabetes: Munich, Germany, 5-9 September 2004
|
|
670
|
|
|
‡a
Author's 40 EASD Annual Meeting of the European Association for the Study of Diabetes: Munich, Germany, 5-9 September 2004
|
|
670
|
|
|
‡a
Author's 40 Reunió anual de l'EASD de l'Associació Europea per a l'Estudi de la Diabetis: Munic, Alemanya, 5-9 de setembre de 2004
|
|
670
|
|
|
‡a
Author's 40th EASD Annual Meeting of the European Association for the Study of Diabetes
|
|
670
|
|
|
‡a
Author's atti di conferenza
|
|
670
|
|
|
‡a
Author's Bariatric surgery in women of childbearing age.
|
|
670
|
|
|
‡a
Author's Chronic kidney disease management in the United Kingdom: NEOERICA project results.
|
|
670
|
|
|
‡a
Author's Continuous glucose monitoring in people with diabetes: the randomized controlled Glucose Level Awareness in Diabetes Study
|
|
670
|
|
|
‡a
Author's Continuous glucose monitoring in people with diabetes: the randomized controlled Glucose Level Awareness in Diabetes Study (GLADIS).
|
|
670
|
|
|
‡a
Author's Derivation and validation of a prediction score for major coronary heart disease events in a U.K. type 2 diabetic population.
|
|
670
|
|
|
‡a
Author's Educational outreach in diabetes to encourage practice nurses to use primary care hypertension and hyperlipidaemia guidelines (EDEN): a randomized controlled trial.
|
|
670
|
|
|
‡a
Author's Effect of Roux-en-Y Bariatric Surgery on Lipoproteins, Insulin Resistance, and Systemic and Vascular Inflammation in Obesity and Diabetes.
|
|
670
|
|
|
‡a
Author's Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial
|
|
670
|
|
|
‡a
Author's Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.
|
|
670
|
|
|
‡a
Author's Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study
|
|
670
|
|
|
‡a
Author's European Association for the Study of Diabetes: Munich, Germany, 5-9 September 2004
|
|
670
|
|
|
‡a
Author's Evaluation of a bedside blood ketone sensor: the effects of acidosis, hyperglycaemia and acetoacetate on sensor performance.
|
|
670
|
|
|
‡a
Author's Evaluation of an electrochemical sensor for measuring blood ketones.
|
|
670
|
|
|
‡a
Author's Factors associated with kidney disease progression and mortality in a referred CKD population.
|
|
670
|
|
|
‡a
Author's Five-year outcome of bariatric surgery in a patient with melanocortin-4 receptor mutation
|
|
670
|
|
|
‡a
Author's Gonadotrophin-releasing hormone analogues: a novel treatment for premenstrual asthma
|
|
670
|
|
|
‡a
Author's Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated?
|
|
670
|
|
|
‡a
Author's In-patient management of diabetes mellitus and patient satisfaction.
|
|
670
|
|
|
‡a
Author's Insulin sensitivity in hypertensive Type 2 diabetic patients after 1 and 19 days' treatment with trandolapril
|
|
670
|
|
|
‡a
Author's Kidney disease management in UK primary care: guidelines, incentives and information technology
|
|
670
|
|
|
‡a
Author's Liraglutide therapy in obese people with type 2 diabetes - experience of a weight management centre.
|
|
670
|
|
|
‡a
Author's Measuring differences in the provision of diabetes care.
|
|
670
|
|
|
‡a
Author's Metabolic outcomes 1 year after gastric bypass surgery in obese people with type 2 diabetes
|
|
670
|
|
|
‡a
Author's Metabolic outcomes 2 years following gastric bypass surgery in people with type 2 diabetes: an observational cohort study
|
|
670
|
|
|
‡a
Author's Monitoring safety in a phase III real-world effectiveness trial: use of novel methodology in the Salford Lung Study
|
|
670
|
|
|
‡a
Author's Obtaining real-world evidence: the Salford Lung Study.
|
|
670
|
|
|
‡a
Author's Polymorphisms in IGF-binding protein 1 are associated with impaired renal function in type 2 diabetes.
|
|
670
|
|
|
‡a
Author's Predictors of remission of type 2 diabetes mellitus after laparoscopic gastric banding and bypass.
|
|
670
|
|
|
‡a
Author's Putting patients in control of data from electronic health records.
|
|
670
|
|
|
‡a
Author's Renal autoregulation is normal in newly diagnosed, normotensive, NIDDM patients.
|
|
670
|
|
|
‡a
Author's Renal enlargement and insulin-like growth factor-1 accumulation in the Wistar rat model of experimental diabetes is not prevented by angiotensin converting enzyme inhibition
|
|
670
|
|
|
‡a
Author's Renal function in long-duration type I diabetes
|
|
670
|
|
|
‡a
Author's Serum phosphate and mortality in patients with chronic kidney disease
|
|
670
|
|
|
‡a
Author's Significance of microalbuminuria in long-duration type 1 diabetes
|
|
670
|
|
|
‡a
Author's Specialist nurse-led clinics to improve control of hypertension and hyperlipidemia in diabetes: economic analysis of the SPLINT trial.
|
|
670
|
|
|
‡a
Author's Specialist nurse-led intervention to treat and control hypertension and hyperlipidemia in diabetes (SPLINT): a randomized controlled trial
|
|
670
|
|
|
‡a
Author's Telemedicine to improve glycaemic control: 3-year results from the Pro-Active Call Centre Treatment Support
|
|
670
|
|
|
‡a
Author's Telemedicine to improve glycaemic control: 3-year results from the Pro-Active Call Centre Treatment Support (PACCTS) trial
|
|
670
|
|
|
‡a
Author's The cost of implementing UK guidelines for the management of chronic kidney disease.
|
|
670
|
|
|
‡a
Author's The evolution of diabetes information systems.
|
|
670
|
|
|
‡a
Author's The languages of health in general practice electronic patient records: a Zipf's law analysis
|
|
670
|
|
|
‡a
Author's The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in asthma.
|
|
670
|
|
|
‡a
Author's The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in chronic obstructive pulmonary disease
|
|
670
|
|
|
‡a
Author's The unrecognized prevalence of chronic kidney disease in diabetes.
|
|
670
|
|
|
‡a
Author's The use of eGFR and ACR to predict decline in renal function in people with diabetes
|
|
670
|
|
|
‡a
Author's Time to move from serum creatinine to eGFR
|
|
670
|
|
|
‡a
Author's Type 2 diabetes whole-genome association study in four populations: the DiaGen consortium
|
|
670
|
|
|
‡a
Author's Using an electronic medical record (EMR) to conduct clinical trials: Salford Lung Study feasibility
|
|
670
|
|
|
‡a
Author's Using the Internet to access confidential patient records: a case study.
|
|
670
|
|
|
‡a
Author's Variation in dialysis patient mortality by Health Authority.
|
|
670
|
|
|
‡a
Author's Variations in process and outcomes of diabetes care by socio-economic status in Salford, UK
|
|
909
|
|
|
‡a
(orcid) 000000034146025x
‡9
1
|
|
912
|
|
|
‡a
40easdannualmeetingoftheeuropeanassociationforthestudyofdiabetesmunichgermany59september
‡A
40 EASD Annual Meeting of the European Association for the Study of Diabetes: Munich, Germany, 5-9 September 2004
‡9
1
|
|
912
|
|
|
‡a
40reunioanualdeleasddelassociacioeuropeaperalestudideladiabetismunicalemanya59desetembrede
‡A
40 Reunió anual de l'EASD de l'Associació Europea per a l'Estudi de la Diabetis: Munic, Alemanya, 5-9 de setembre de 2004
‡9
1
|
|
912
|
|
|
‡a
40theasdannualmeetingoftheeuropeanassociationforthestudyofdiabetes
‡A
40th EASD Annual Meeting of the European Association for the Study of Diabetes
‡9
1
|
|
912
|
|
|
‡a
atti501conferenza
‡A
atti di conferenza
‡9
1
|
|
912
|
|
|
‡a
europeanassociationforthestudyofdiabetesmunichgermany59september
‡A
European Association for the Study of Diabetes: Munich, Germany, 5-9 September 2004
‡9
1
|
|
912
|
|
|
‡a
40easdannualmeetingofdeeuropeanassociationgivedestudyofdiabetesmunichgermany59september
‡A
40 EASD Annual Meeting of de European Association give de Study of Diabetes: Munich, Germany, 5-9 September 2004
‡9
1
|
|
919
|
|
|
‡a
bariatricsurgeryinwomenofchildbearingage
‡A
Bariatric surgery in women of childbearing age.
‡9
1
|
|
919
|
|
|
‡a
chronickidneydiseasemanagementintheunitedkingdomneoericaprojectresults
‡A
Chronic kidney disease management in the United Kingdom: NEOERICA project results.
‡9
1
|
|
919
|
|
|
‡a
continuousglucosemonitoringinpeoplewithdiabetestherandomizedcontrolledglucoselevelawarenessindiabetesstudy
‡A
Continuous glucose monitoring in people with diabetes: the randomized controlled Glucose Level Awareness in Diabetes Study
‡9
1
|
|
919
|
|
|
‡a
continuousglucosemonitoringinpeoplewithdiabetestherandomizedcontrolledglucoselevelawarenessindiabetesstudygladis
‡A
Continuous glucose monitoring in people with diabetes: the randomized controlled Glucose Level Awareness in Diabetes Study (GLADIS).
‡9
1
|
|
919
|
|
|
‡a
derivationandvalidationofapredictionscoreformajorcoronaryheartdiseaseeventsinauktype2diabeticpopulation
‡A
Derivation and validation of a prediction score for major coronary heart disease events in a U.K. type 2 diabetic population.
‡9
1
|
|
919
|
|
|
‡a
educationaloutreachindiabetestoencouragepracticenursestouseprimarycarehypertensionandhyperlipidaemiaguidelinesedenarandomizedcontrolledtrial
‡A
Educational outreach in diabetes to encourage practice nurses to use primary care hypertension and hyperlipidaemia guidelines (EDEN): a randomized controlled trial.
‡9
1
|
|
919
|
|
|
‡a
effectofrouxenybariatricsurgeryonlipoproteinsinsulinresistanceandsystemicandvascularinflammationinobesityanddiabetes
‡A
Effect of Roux-en-Y Bariatric Surgery on Lipoproteins, Insulin Resistance, and Systemic and Vascular Inflammation in Obesity and Diabetes.
‡9
1
|
|
919
|
|
|
‡a
effectivenessoffluticasonefuroateplusvilanterolonasthmacontrolinclinicalpracticeanopenlabelparallelgrouprandomisedcontrolledtrial
‡A
Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial
‡9
1
|
|
919
|
|
|
‡a
effectivenessoffluticasonefuroatevilanterolforcopdinclinicalpractice
‡A
Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.
‡9
1
|
|
919
|
|
|
‡a
effectivenessoffluticasonefuroatevilanterolversusfluticasonepropionatesalmeterolonasthmacontrolinthesalfordlungstudy
‡A
Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study
‡9
1
|
|
919
|
|
|
‡a
evaluationofabedsidebloodketonesensortheeffectsofacidosishyperglycaemiaandacetoacetateonsensorperformance
‡A
Evaluation of a bedside blood ketone sensor: the effects of acidosis, hyperglycaemia and acetoacetate on sensor performance.
‡9
1
|
|
919
|
|
|
‡a
evaluationofanelectrochemicalsensorformeasuringbloodketones
‡A
Evaluation of an electrochemical sensor for measuring blood ketones.
‡9
1
|
|
919
|
|
|
‡a
factorsassociatedwithkidneydiseaseprogressionandmortalityinareferredckdpopulation
‡A
Factors associated with kidney disease progression and mortality in a referred CKD population.
‡9
1
|
|
919
|
|
|
‡a
5yearoutcomeofbariatricsurgeryinapatientwithmelanocortin4receptormutation
‡A
Five-year outcome of bariatric surgery in a patient with melanocortin-4 receptor mutation
‡9
1
|
|
919
|
|
|
‡a
gonadotrophinreleasinghormoneanaloguesanoveltreatmentforpremenstrualasthma
‡A
Gonadotrophin-releasing hormone analogues: a novel treatment for premenstrual asthma
‡9
1
|
|
919
|
|
|
‡a
impairedglucosetoleranceandinsulinresistanceinheartfailureunderrecognizedandundertreated
‡A
Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated?
‡9
1
|
|
919
|
|
|
‡a
inpatientmanagementofdiabetesmellitusandpatientsatisfaction
‡A
In-patient management of diabetes mellitus and patient satisfaction.
‡9
1
|
|
919
|
|
|
‡a
insulinsensitivityinhypertensivetype2diabeticpatientsafter1and19daystreatmentwithtrandolapril
‡A
Insulin sensitivity in hypertensive Type 2 diabetic patients after 1 and 19 days' treatment with trandolapril
‡9
1
|
|
919
|
|
|
‡a
kidneydiseasemanagementinukprimarycareguidelinesincentivesandinformationtechnology
‡A
Kidney disease management in UK primary care: guidelines, incentives and information technology
‡9
1
|
|
919
|
|
|
‡a
liraglutidetherapyinobesepeoplewithtype2diabetesexperienceofaweightmanagementcentre
‡A
Liraglutide therapy in obese people with type 2 diabetes - experience of a weight management centre.
‡9
1
|
|
919
|
|
|
‡a
measuringdifferencesintheprovisionofdiabetescare
‡A
Measuring differences in the provision of diabetes care.
‡9
1
|
|
919
|
|
|
‡a
metabolicoutcomes1yearaftergastricbypasssurgeryinobesepeoplewithtype2diabetes
‡A
Metabolic outcomes 1 year after gastric bypass surgery in obese people with type 2 diabetes
‡9
1
|
|
919
|
|
|
‡a
metabolicoutcomes2yearsfollowinggastricbypasssurgeryinpeoplewithtype2diabetesanobservationalcohortstudy
‡A
Metabolic outcomes 2 years following gastric bypass surgery in people with type 2 diabetes: an observational cohort study
‡9
1
|
|
919
|
|
|
‡a
monitoringsafetyinaphase3realworldeffectivenesstrialuseofnovelmethodologyinthesalfordlungstudy
‡A
Monitoring safety in a phase III real-world effectiveness trial: use of novel methodology in the Salford Lung Study
‡9
1
|
|
919
|
|
|
‡a
obtainingrealworldevidencethesalfordlungstudy
‡A
Obtaining real-world evidence: the Salford Lung Study.
‡9
1
|
|
919
|
|
|
‡a
polymorphismsinigfbindingprotein1areassociatedwithimpairedrenalfunctionintype2diabetes
‡A
Polymorphisms in IGF-binding protein 1 are associated with impaired renal function in type 2 diabetes.
‡9
1
|
|
919
|
|
|
‡a
predictorsofremissionoftype2diabetesmellitusafterlaparoscopicgastricbandingandbypass
‡A
Predictors of remission of type 2 diabetes mellitus after laparoscopic gastric banding and bypass.
‡9
1
|
|
919
|
|
|
‡a
puttingpatientsincontrolofdatafromelectronichealthrecords
‡A
Putting patients in control of data from electronic health records.
‡9
1
|
|
919
|
|
|
‡a
renalautoregulationisnormalinnewlydiagnosednormotensiveniddmpatients
‡A
Renal autoregulation is normal in newly diagnosed, normotensive, NIDDM patients.
‡9
1
|
|
919
|
|
|
‡a
renalenlargementandinsulinlikegrowthfactor1accumulationinthewistarratmodelofexperimentaldiabetesisnotpreventedbyangiotensinconvertingenzymeinhibition
‡A
Renal enlargement and insulin-like growth factor-1 accumulation in the Wistar rat model of experimental diabetes is not prevented by angiotensin converting enzyme inhibition
‡9
1
|
|
919
|
|
|
‡a
renalfunctioninlongdurationtype1diabetes
‡A
Renal function in long-duration type I diabetes
‡9
1
|
|
919
|
|
|
‡a
serumphosphateandmortalityinpatientswithchronickidneydisease
‡A
Serum phosphate and mortality in patients with chronic kidney disease
‡9
1
|
|
919
|
|
|
‡a
significanceofmicroalbuminuriainlongdurationtype1diabetes
‡A
Significance of microalbuminuria in long-duration type 1 diabetes
‡9
1
|
|
919
|
|
|
‡a
specialistnurseledclinicstoimprovecontrolofhypertensionandhyperlipidemiaindiabeteseconomicanalysisofthesplinttrial
‡A
Specialist nurse-led clinics to improve control of hypertension and hyperlipidemia in diabetes: economic analysis of the SPLINT trial.
‡9
1
|
|
919
|
|
|
‡a
specialistnurseledinterventiontotreatandcontrolhypertensionandhyperlipidemiaindiabetessplintarandomizedcontrolledtrial
‡A
Specialist nurse-led intervention to treat and control hypertension and hyperlipidemia in diabetes (SPLINT): a randomized controlled trial
‡9
1
|
|
919
|
|
|
‡a
telemedicinetoimproveglycaemiccontrol3yearresultsfromtheproactivecallcentretreatmentsupport
‡A
Telemedicine to improve glycaemic control: 3-year results from the Pro-Active Call Centre Treatment Support
‡9
1
|
|
919
|
|
|
‡a
telemedicinetoimproveglycaemiccontrol3yearresultsfromtheproactivecallcentretreatmentsupportpacctstrial
‡A
Telemedicine to improve glycaemic control: 3-year results from the Pro-Active Call Centre Treatment Support (PACCTS) trial
‡9
1
|
|
919
|
|
|
‡a
costofimplementingukguidelinesforthemanagementofchronickidneydisease
‡A
The cost of implementing UK guidelines for the management of chronic kidney disease.
‡9
1
|
|
919
|
|
|
‡a
evolutionofdiabetesinformationsystems
‡A
The evolution of diabetes information systems.
‡9
1
|
|
919
|
|
|
‡a
languagesofhealthingeneralpracticeelectronicpatientrecordsazipfslawanalysis
‡A
The languages of health in general practice electronic patient records: a Zipf's law analysis
‡9
1
|
|
919
|
|
|
‡a
salfordlungstudyprotocolapragmaticrandomisedphase3realworldeffectivenesstrialinasthma
‡A
The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in asthma.
‡9
1
|
|
919
|
|
|
‡a
salfordlungstudyprotocolapragmaticrandomisedphase3realworldeffectivenesstrialinchronicobstructivepulmonarydisease
‡A
The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in chronic obstructive pulmonary disease
‡9
1
|
|
919
|
|
|
‡a
unrecognizedprevalenceofchronickidneydiseaseindiabetes
‡A
The unrecognized prevalence of chronic kidney disease in diabetes.
‡9
1
|
|
919
|
|
|
‡a
useofegfrandacrtopredictdeclineinrenalfunctioninpeoplewithdiabetes
‡A
The use of eGFR and ACR to predict decline in renal function in people with diabetes
‡9
1
|
|
919
|
|
|
‡a
timetomovefromserumcreatininetoegfr
‡A
Time to move from serum creatinine to eGFR
‡9
1
|
|
919
|
|
|
‡a
type2diabeteswholegenomeassociationstudyin4populationsthediagenconsortium
‡A
Type 2 diabetes whole-genome association study in four populations: the DiaGen consortium
‡9
1
|
|
919
|
|
|
‡a
usinganelectronicmedicalrecordemrtoconductclinicaltrialssalfordlungstudyfeasibility
‡A
Using an electronic medical record (EMR) to conduct clinical trials: Salford Lung Study feasibility
‡9
1
|
|
919
|
|
|
‡a
usingtheinternettoaccessconfidentialpatientrecordsacasestudy
‡A
Using the Internet to access confidential patient records: a case study.
‡9
1
|
|
919
|
|
|
‡a
variationindialysispatientmortalitybyhealthauthority
‡A
Variation in dialysis patient mortality by Health Authority.
‡9
1
|
|
919
|
|
|
‡a
variationsinprocessandoutcomesofdiabetescarebysocioeconomicstatusinsalforduk
‡A
Variations in process and outcomes of diabetes care by socio-economic status in Salford, UK
‡9
1
|
|
943
|
|
|
‡a
200x
‡A
2004
‡9
4
|
|
946
|
|
|
‡a
b
‡9
1
|
|
996
|
|
|
‡2
CAOONL|ncf10130277
|
|
996
|
|
|
‡2
LC|n 92010111
|
|
996
|
|
|
‡2
NLA|000035819830
|
|
996
|
|
|
‡2
SUDOC|119661586
|
|
996
|
|
|
‡2
ISNI|0000000032703457
|
|
996
|
|
|
‡2
ISNI|000000004345744X
|
|
996
|
|
|
‡2
ISNI|0000000061385136
|
|
996
|
|
|
‡2
RERO|A003637559
|
|
996
|
|
|
‡2
DNB|122248058
|
|
996
|
|
|
‡2
LC|n 91041912
|
|
996
|
|
|
‡2
RERO|A022947102
|
|
996
|
|
|
‡2
BIBSYS|99044025
|
|
996
|
|
|
‡2
ISNI|0000000074744214
|
|
996
|
|
|
‡2
ISNI|0000000065795722
|
|
996
|
|
|
‡2
LC|n 50060781
|
|
996
|
|
|
‡2
LC|no 97007540
|
|
996
|
|
|
‡2
ISNI|0000000040871696
|
|
996
|
|
|
‡2
LC|nr 93028313
|
|
996
|
|
|
‡2
ISNI|0000000029392360
|
|
996
|
|
|
‡2
J9U|987007278232205171
|
|
996
|
|
|
‡2
CAOONL|ncf10364728
|
|
996
|
|
|
‡2
DNB|101913834
|
|
996
|
|
|
‡2
ISNI|0000000052890659
|
|
996
|
|
|
‡2
NTA|303286474
|
|
996
|
|
|
‡2
LNB|LNC10-000118791
|
|
996
|
|
|
‡2
DNB|103338027X
|
|
996
|
|
|
‡2
ISNI|0000000036984129
|
|
996
|
|
|
‡2
ISNI|000000008390788X
|
|
996
|
|
|
‡2
RERO|A003341239
|
|
996
|
|
|
‡2
DNB|124962653
|
|
996
|
|
|
‡2
ISNI|000000003315527X
|
|
996
|
|
|
‡2
PLWABN|9811341949305606
|
|
996
|
|
|
‡2
LC|n 90608452
|
|
996
|
|
|
‡2
NII|DA0405832X
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
